Iris de Nie

73 SUCCESSFUL RESTORATION OF SPERMATOGENESIS FOLLOWING GENDER-AFFIRMING HORMONE THERAPY 5 Patient 5 Patient 6 Patient 7 Patient 8 Patient 9 decreased to 2 mg/ day n/a temporarily used a decreased dose of 2mg/ day 27 36 29 33 33 estradiol valerate 2 mg/day estradiol valerate 2 mg/twice a day 4mg/day estradiol valerate 2 mg/ twice a day estradiol valerate 2mg/ twice a day 36 36 14 56 (period of cessation in 2014) 36 24 33 28 27 29 spironolactone cyproterone acetate cyproterone acetate cyproterone acetate cyproterone acetate 100 mg/day 50 mg/day 25 mg/day 50 mg/twice a day 50 mg/day decrease dose to 12,5 mg/day Switched to 25 mg/ alternate days after 6 months dose decreased to 20 mg/day 27 36 29 33 33 spirinolactone 100 mg/day cyproterone acetate 12.5 mg/day 25 mg/alternate days 20mg/day 50 mg/day 36 36 14 56 (period of cessation in 2014) 40 none none none none none none breast development, decreased facial hair growth Tanner stage 3-4 breast development breast development decreased muscle strength, decreased body hair growth, softer skin, breast development n.d. 15 months after starting hormones 13 months after commencement of oestrogen 24 months after re- initiation of HT 36 months after commencement estradiol, 40 months after commencement anti-androgens n.d. 246 556 320 154 n.d. 4.4 0.9 0.7 0.4 n.d. 1.1 0.2 1.2 < 0.1 n.d. n.d. n.d. n.d. n.d.